Amarin reported $-2.26M in EBIT for its fiscal quarter ending in December of 2025.





Ebit Change Date
AbbVie USD 6.72B 1.99B Jun/2026
Alnylam Pharmaceuticals USD 112.6M 24.99M Jun/2026
Amarin USD -2.26M 564K Dec/2025
AstraZeneca USD 3.16B 3.95B Jun/2026
BioCryst Pharmaceuticals USD 260.38M 230.79M Dec/2025
DBV Technologies USD -47.9M 2.85M Mar/2026
GlaxoSmithKline GBP 2.6B 312M Jun/2026
Halozyme Therapeutics USD -61.77M 26.64M Mar/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Neurocrine Biosciences USD 219.9M 5.3M Jun/2026
Novartis USD 4.73B 549M Jun/2026